Halozyme Therapeutics, Inc.HALO
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $1.51B, growing 39.1% year-over-year. TTM net income stood at $348.84M (28.1% contraction). Quarterly EBITDA was $188.74M and operating income was $184.52M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze HALO growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters